AstraZeneca’s shareholders rebel over pay

Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.

Drug giant AstraZeneca has suffered a “major shareholder rebellion” over proposals to raise bonus levels for its bosses, including CEO Pascal Soriot (pictured), says Julia Bradshaw in The Daily Telegraph. While the proposals were passed, over 40% of AstraZeneca’s investors voted against them. 

Soriot’s possible earnings have now climbed from 650% of his salary to 900% in just two years. The reason the revolt went as far as it did was due to opposition from Institutional Shareholder Services (ISS), which advises 4,000 clients on how they should vote, says Oliver Shah in the Sunday Times. However, while the likes of ISS can be useful in fighting “egregious bonuses”, such as those at floundering Cineworld, their “box-ticking” is unfair for Soriot, one of the few “world-class chief executives in the FTSE 100”. AstraZeneca’s share price has increased by 80% since he took over and it has developed a Covid-19 vaccine with Oxford, so“if anyone deserves a pay rise, it is Soriot”.

Soriot is a “talented chief” whose performance “actually lives up to the multimillion-pound billing” and his pay isn’t excessive compared with his contemporaries at Roche or Pfizer, says Helen Thomas in the Financial Times. Still, investors rightly worry that the dynamic in the AstraZeneca boardroom has “tipped” in favour of its “superstar boss”, who is now “being feted as the saviour of the UK’s health and economy”. The increased size and complexity that AstraZeneca is taking on with its $39bn takeover of Alexion, which shareholders also approved at the meeting, could prompt Soriot to demand even more money in future.

Recommended

Persimmon yields 12.3%, but can you trust the company to deliver?
Share tips

Persimmon yields 12.3%, but can you trust the company to deliver?

With a dividend yield of 12.3%, Persimmon looks like a highly attractive prospect for income investors. But that sort of yield can also indicate compa…
1 Jul 2022
The MoneyWeek Podcast: nuggets of positivity in an extended bear market
Investment strategy

The MoneyWeek Podcast: nuggets of positivity in an extended bear market

Merryn and John talk about he need for higher wages and lower house prices, and why the fact that this is the least dramatic bear market they’ve ever …
1 Jul 2022
Here are the best savings accounts on the market now
Savings

Here are the best savings accounts on the market now

With inflation at more than 9%, your savings are not going to keep pace with the rising cost of living. But you can at least slow the rate at which yo…
1 Jul 2022
Don’t try to time the bottom – start buying good companies now
Investment strategy

Don’t try to time the bottom – start buying good companies now

Markets are having a rough time, so you may be tempted to wait to try to call the bottom and pick up some bargains. But that would be a mistake, says …
1 Jul 2022

Most Popular

UK house prices are definitely cooling off – but are they heading for a fall?
House prices

UK house prices are definitely cooling off – but are they heading for a fall?

UK house prices hit a fresh high in June, but as interest rates start to rise, the market is cooling John Stepek assesses just how much of an effect h…
30 Jun 2022
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
22 Jun 2022
Gold has been incredibly boring to own – but that’s no bad thing right now
Gold

Gold has been incredibly boring to own – but that’s no bad thing right now

Stocks, bonds and cryptocurrencies have all seen big falls this year. But gold remains at its one-year average. It may be dull, but it’s doing what it…
29 Jun 2022